The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Genetic polymorphism in the genes encoding the human leukocyte antigen (HLA) molecules enables presentation of a wide range peptide ligands thus maximising immune surveillance of pathogens. A consequence of the diversification of the HLA Ag-binding pocket is the enhanced opportunity for off-target binding of small drugs by HLA molecules, with subsequent immune reactivity. These potential off-target interactions are ‘set up’ to generate T cell-mediated adverse drug reactions even though the precise mechanisms of most HLA-drug interactions are still poorly understood. The association between abacavir hypersensitivity syndrome and HLA-B*57:01 is one exception that has been resolved at a molecular and mechanistic level. Here, we explore the road to understanding the interaction between abacavir and the HLA-B*57:01 molecule and review the current state of understanding of interactions between other drugs and HLA molecules implicated in adverse drug reactions, which appear to involve multiple mechanisms. The continued expansion of the pharmacopoeia generates an imperative to understand these interactions at the molecular level in order to prevent the continued burden on individuals and the health care system.

Original languageEnglish
Pages (from-to)617-630
Number of pages14
JournalImmunogenetics
Volume69
Issue number8-9
DOIs
Publication statusPublished - Aug 2017

Keywords

  • Abacavir
  • Adverse drug reactions
  • Antigen processing and presentation
  • Human leukocyte antigen
  • Major histocompatibility complex

Cite this

@article{a9e235dbe898425b8b1bfb53d4aad905,
title = "The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions",
abstract = "Genetic polymorphism in the genes encoding the human leukocyte antigen (HLA) molecules enables presentation of a wide range peptide ligands thus maximising immune surveillance of pathogens. A consequence of the diversification of the HLA Ag-binding pocket is the enhanced opportunity for off-target binding of small drugs by HLA molecules, with subsequent immune reactivity. These potential off-target interactions are ‘set up’ to generate T cell-mediated adverse drug reactions even though the precise mechanisms of most HLA-drug interactions are still poorly understood. The association between abacavir hypersensitivity syndrome and HLA-B*57:01 is one exception that has been resolved at a molecular and mechanistic level. Here, we explore the road to understanding the interaction between abacavir and the HLA-B*57:01 molecule and review the current state of understanding of interactions between other drugs and HLA molecules implicated in adverse drug reactions, which appear to involve multiple mechanisms. The continued expansion of the pharmacopoeia generates an imperative to understand these interactions at the molecular level in order to prevent the continued burden on individuals and the health care system.",
keywords = "Abacavir, Adverse drug reactions, Antigen processing and presentation, Human leukocyte antigen, Major histocompatibility complex",
author = "Illing, {Patricia T.} and Purcell, {Anthony W.} and James McCluskey",
year = "2017",
month = "8",
doi = "10.1007/s00251-017-1007-5",
language = "English",
volume = "69",
pages = "617--630",
journal = "Immunogenetics",
issn = "0093-7711",
publisher = "Springer",
number = "8-9",

}

The role of HLA genes in pharmacogenomics : unravelling HLA associated adverse drug reactions. / Illing, Patricia T.; Purcell, Anthony W.; McCluskey, James.

In: Immunogenetics, Vol. 69, No. 8-9, 08.2017, p. 617-630.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - The role of HLA genes in pharmacogenomics

T2 - unravelling HLA associated adverse drug reactions

AU - Illing, Patricia T.

AU - Purcell, Anthony W.

AU - McCluskey, James

PY - 2017/8

Y1 - 2017/8

N2 - Genetic polymorphism in the genes encoding the human leukocyte antigen (HLA) molecules enables presentation of a wide range peptide ligands thus maximising immune surveillance of pathogens. A consequence of the diversification of the HLA Ag-binding pocket is the enhanced opportunity for off-target binding of small drugs by HLA molecules, with subsequent immune reactivity. These potential off-target interactions are ‘set up’ to generate T cell-mediated adverse drug reactions even though the precise mechanisms of most HLA-drug interactions are still poorly understood. The association between abacavir hypersensitivity syndrome and HLA-B*57:01 is one exception that has been resolved at a molecular and mechanistic level. Here, we explore the road to understanding the interaction between abacavir and the HLA-B*57:01 molecule and review the current state of understanding of interactions between other drugs and HLA molecules implicated in adverse drug reactions, which appear to involve multiple mechanisms. The continued expansion of the pharmacopoeia generates an imperative to understand these interactions at the molecular level in order to prevent the continued burden on individuals and the health care system.

AB - Genetic polymorphism in the genes encoding the human leukocyte antigen (HLA) molecules enables presentation of a wide range peptide ligands thus maximising immune surveillance of pathogens. A consequence of the diversification of the HLA Ag-binding pocket is the enhanced opportunity for off-target binding of small drugs by HLA molecules, with subsequent immune reactivity. These potential off-target interactions are ‘set up’ to generate T cell-mediated adverse drug reactions even though the precise mechanisms of most HLA-drug interactions are still poorly understood. The association between abacavir hypersensitivity syndrome and HLA-B*57:01 is one exception that has been resolved at a molecular and mechanistic level. Here, we explore the road to understanding the interaction between abacavir and the HLA-B*57:01 molecule and review the current state of understanding of interactions between other drugs and HLA molecules implicated in adverse drug reactions, which appear to involve multiple mechanisms. The continued expansion of the pharmacopoeia generates an imperative to understand these interactions at the molecular level in order to prevent the continued burden on individuals and the health care system.

KW - Abacavir

KW - Adverse drug reactions

KW - Antigen processing and presentation

KW - Human leukocyte antigen

KW - Major histocompatibility complex

UR - http://www.scopus.com/inward/record.url?scp=85022221620&partnerID=8YFLogxK

U2 - 10.1007/s00251-017-1007-5

DO - 10.1007/s00251-017-1007-5

M3 - Review Article

VL - 69

SP - 617

EP - 630

JO - Immunogenetics

JF - Immunogenetics

SN - 0093-7711

IS - 8-9

ER -